Skip to main content
SAMJIN PHARMACEUTICAL CO.,LTD logo

SAMJIN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 005500 ISIN · KR7005500004 KO Manufacturing
Open in API
Filings indexed 249 across all filing types
Latest filing 2025-08-21 Major Shareholding Noti…
Country KR South Korea
Listing KO 005500

About SAMJIN PHARMACEUTICAL CO.,LTD

https://www.samjinpharm.co.kr/

Samjin Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of medicines. The company's portfolio includes a wide range of over-the-counter (OTC) and prescription drugs, offered in various formulations such as oral, drop, and injectable forms. Notable products include the analgesic Gevorin, the antiplatelet agent Plavix, and the hypercholesterolemia treatment Newstatin-R. A central part of its strategy is a strong commitment to R&D, focusing on creating innovative new drugs to address diseases with high unmet medical needs. The company actively develops novel therapeutics for severe conditions, including cardiovascular, respiratory, and gastrointestinal diseases, with the goal of becoming a global pharmaceutical innovator.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details the shareholding status, changes in ownership, and collateral agreements (pledges) of major shareholders and their special relations. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-08-21 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-Annual Report) for Samjin Pharmaceutical Co., Ltd., covering the period from January 1, 2025, to June 30, 2025. It contains comprehensive financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-14 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and major contracts (such as collateral agreements) of major shareholders and their special relations. This type of filing is specifically categorized as a Major Shareholding Notification (MRQ) in the provided schema.
2025-07-29 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in share ownership, and collateral agreements of major shareholders (Cho Eui-hwan and related parties) in Samjin Pharmaceutical. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-07-21 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. This type of filing is a mandatory disclosure of insider trading or changes in share ownership by company directors or major shareholders. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2025-07-07 Korean
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for Samjin Pharmaceutical Co., Ltd. covering the period from January 1, 2025, to March 31, 2025. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-15 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.